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ABSTRACT. Lactic acid bacteria (LAB) are an attractive and safe 
alternative for the expression of heterologous proteins, as they are 
nonpathogenic and endotoxin-free organisms. Lactococcus lactis, 
the LAB model organism, has been extensively employed in the 
biotechnology field for large-scale production of heterologous proteins, 
and its use as a “cell factory” has been widely studied. We have been 
particularly interested in the use of L. lactis for production of heat shock 
proteins (HSPs), which reportedly play important roles in the initiation 
of innate and adaptive immune responses. However, this activity has 
been questioned, as LPS contamination appears to be responsible 
for most, if not all, immunostimulatory activity of HSPs. In order to 
study the effect of pure HSPs on the immune system, we constructed 
recombinant L. lactis strains able to produce and properly address the 
Mycobacterium leprae 65-kDa HSP (Hsp65) to the cytoplasm or to 
the extracellular medium, using a xylose-induced expression system. 
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Approximately 7 mg/L recombinant Hsp65 was secreted. Degradation 
products related to lactococcal HtrA activity were not observed, and the 
Limulus amebocyte lysate assay demonstrated that the amount of LPS 
in the recombinant Hsp65 preparations was 10-100 times lower than the 
permitted levels established by the U.S. Food and Drug Administration. 
These new L. lactis strains will allow investigation of the effects of M. 
leprae Hsp65 without the interference of LPS; consequently, they have 
potential for a variety of biotechnological, medical and therapeutic 
applications.
Key words: Heat shock proteins; LPS-free Hsp65; Lactococcus lactis; 
Mycobacterium leprae
INTRODUCTION
Over the last 30 years, there have been considerable advances in technology for pro-
ducing recombinant proteins in bacterial expression systems. The use of bacteria to produce 
recombinant proteins is very attractive because they are genetically well-characterized and 
because they are easy to culture on inexpensive substrates (Brondyk, 2009). Escherichia coli 
was the first bacterial host used to produce recombinant proteins and remains one of the most 
widely used bacteria for the expression of heterologous proteins. The advantage of E. coli 
consists in its ability to produce proteins in large quantities and to grow very quickly. How-
ever, despite these useful characteristics, it also has some drawbacks (Terpe, 2006; Demain 
and Vaishnav, 2009). The main problem associated with the use of E. coli is the accumula-
tion of endotoxins (referred to as lipopolysaccharides - LPS). LPS are large molecules found 
in the outer membrane of Gram-negative bacterial cell walls that can bind to many kinds of 
receptors, resulting in the activation of various types of intracellular signaling pathways and 
production of proinflammatory cytokines. Consequently, LPS acts as a powerful activator of 
innate immune responses and is responsible for endotoxic shock (Cardoso et al., 2007; Bryant 
et al., 2010). Moreover, this bacterium cannot express very large proteins and high expression 
of recombinant protein often leads to the accumulation of inactive protein aggregates (inclu-
sion bodies) (Brondyk, 2009).
To overcome these limitations, lactic acid bacteria (LAB) have emerged as an attrac-
tive and safe alternative, not only due to their “GRAS” (Generally Regarded As Safe) status 
granted by the U.S. Food and Drug Administration (FDA), but also because they are noninva-
sive, nonpathogenic, endotoxin-free and do not form inclusion bodies (Wells and Mercenier, 
2008). Lactococcus lactis, the LAB model, has been widely used for large-scale production of 
heterologous proteins for the last two decades (Mierau and Kleerebezem, 2005). Its metabo-
lism is relatively simple and well-known, and laboratory strains do not produce the extracyto-
plasmic protease PrtP. Furthermore, there are several genetic tools available for the production 
of heterologous proteins in L. lactis (Morello et al., 2008). Its genetic accessibility has allowed 
a variety of new applications to be developed, beyond its traditional use in food fermentation. 
For example L. lactis has been genetically engineered to produce cytokines (Marinho et al., 
2010), enzymes (Du et al., 2010), membrane proteins (Frelet-Barrand et al., 2010), and bacte-
rial and viral antigens, expressed either intra- or extracellularly (Van Huynegem et al., 2009). 
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Therefore, its use as a “cell factory” has been extensively studied.
We have been particularly interested in the use of L. lactis as a factory for the produc-
tion of heat shock proteins (HSPs), which is a group of molecular chaperones that are highly 
conserved across species. Their expression is induced by a wide variety of stresses (including 
high temperature, anoxia, and ethanol) (Lindquist and Craig, 1988). Under stress conditions, 
HSPs promote selective degradation of misfolded proteins and they prevent protein aggrega-
tion by facilitating their correct conformation (Rajaiah and Moudgil, 2009). These proteins 
have also been reported to play important roles in the initiation of innate as well as adaptive 
immune responses by activating antigen-presenting cells, such as dendritic cells and macro-
phages (Tsan and Gao, 2009). However, the immunostimulatory activity of HSPs has been 
questioned. Molecules such as LPS and other endotoxins have the same effect on the immune 
system (Osterloh et al., 2007). Gao and Tsan (2003) demonstrated that the reported proinflam-
matory cytokine-inducing effect of 60- and 70-kDa HSP (Hsp60 and Hsp70) is due to contam-
ination with LPS and LPS-associated molecules. These contaminants appear to be responsible 
for most, if not all, of the reported in vitro capacity to induce intracellular signalling, as highly 
purified HSPs did not alter cell function, such as upregulation and/or downregulation of genes 
that control cytokine production (Tsan and Gao, 2009).
To be able to study how pure HSPs affect the immune system, we constructed recom-
binant L. lactis strains secreting Mycobacterium leprae 65-kDa HSP (Hsp65), using a xylose-
inducible expression system (XIES) (Miyoshi et al., 2004). This protein is reported to be an 
immunodominant antigen eliciting both humoral and cellular responses. Immunization with 
DNA-hsp65 produced prophylactic and therapeutic effects in a murine model of tuberculosis 
(Silva, 1999). This protein also induced the reduction of established tumors in mouse models 
(Victora et al., 2009), and it is protective against experimentally induced arthritis in mice 
(Santos-Junior et al., 2005). These L. lactis strains offer the significant advantage of produc-
ing recombinant Hsp65 that is endotoxin-free, which could be used for biotechnological and 
therapeutic applications.
MATERIAL AND METHODS
Bacterial strains, plasmids and growth conditions
Bacterial strains and plasmids used in this study are listed in Table 1. The L. lactis 
NCD02118 strains were grown in Difco M17 broth, supplemented with 0.5% glucose (GM17) 
or 1% xylose (XM17), at 30°C, without agitation. When required, 10 µg/mL chloramphenicol 
was added to the medium. The E. coli strains were aerobically grown at 37°C in Luria-Bertani 
medium containing 100 µg/mL ampicillin or 10 µg/mL chloramphenicol, when needed.
DNA manipulation
The procedures for DNA manipulation were carried out as described by Sambrook et 
al. (1989), with a few modifications. The plasmids were purified by the alkaline lysis method, 
and the quality of the products that were obtained, including their concentration and purity, 
was determined by measuring absorbance at 260 and 280 nm in a spectrophotometer (Bio-
Photometer plus Eppendorf). Restriction and modification endonucleases, as well as ligation 
reactions, were used and run according to recommendations of the supplier (Invitrogen).
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Cloning and expression of recombinant M. leprae Hsp65 in E. coli and L. lactis
To construct L. lactis strains producing either cytoplasmic (CYT) or secreted 
(SEC) forms of the M. leprae Hsp65 antigen, the hsp65 ORF was PCR-amplified from the 
pcDNA3:hsp65 plasmid (Table 1). The primers that were used, which contained an artificial 
restriction site at both extremities, were based on the genomic DNA sequence of M. leprae 
TN (GenBank Accession No. M14341). These primers are listed in Table 2. Subsequently, 
the amplicons corresponding to the CYT and SEC forms of the antigen were cloned into the 
pCR®-Blunt II-TOPO® in E. coli TOP10 to generate the intermediate plasmids: pTP:chsp65 
and pTP:shsp65. These plasmids were later digested with the restriction endonucleases NsiI 
and EcoRI, allowing the release of the ORFs “CYThsp65” and “SEChsp65”. These fragments 
were purified and cloned into “pXylT:CYT” and “pXylT:SEC” backbones, respectively, which 
were purified from NsiI/EcoRI cut of pXylT:CYT:nuc and pXylT:SEC:nuc. The final plasmids, 
pXylT:CYT:hsp65 and pXylT:SEC:hsp65 (Figure 1), were first obtained in E. coli and then 
transferred to L. lactis NCDO2118 by electroporation. The presence of the expression vectors 
with the inserts was confirmed by PCR and DNA sequencing.
Conditions of xylose induction
On the first day, a single colony of wild-type or recombinant L. lactis NCDO2118 
(harboring pXylT:CYT:hsp65 or pXylT:SEC:hsp65) was grown at 30°C, without agitation, 
in 5 mL GM17, containing 10 µg/mL chloramphenicol, when needed. On the second day, 
the overnight culture was diluted 1:10,000 in 10 mL fresh XM17, supplemented with 10 µg/
mL chloramphenicol, when required, to induce the expression of the hsp65 ORF. On the third 
day, when a 2.0 optical density at 600 nm (OD600 nm) was reached, protein was extracted and 
analyzed by Western blotting.
Figure 1. Schematic representation of the xylose-inducible expression vectors for intracellular or extracellular 
production of rHsp65. For details of plasmid construction, see the text. PxylT = xylose-inducible promoter; 
RBSUsp45 = ribosome binding site of Usp45; rHsp65 = recombinant Mycobacterium leprae hsp65 coding 
sequence; Cm = chloramphenicol resistance; SP = signal peptide; repA and repC = replication origin; EcoRI and 
NsiI = restriction enzymes.
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Protein extractions
Protein sample preparation from L. lactis cultures was performed as previously de-
scribed (Le Loir et al., 1998), with some modifications. Samples were prepared from 2 mL 
both induced and noninduced cultures. Next, they were centrifuged for 10 min at 4°C, at 
12,000 g. Later, the supernatant and the pellet were treated separately. The supernatant was 
run through a 0.2-µm pore-size filter and 100 µL 100% trichloroacetic acid was then added 
for protein precipitation. Dithiothreitol (DTT; 10 mM) and 1 mM phenylmethylsulfonyl 
fluoride (PMSF) were also added to the filtrate. This was then incubated for 1 h on ice and 
centrifuged (20 min, 12,000 g, 4°C). The pellet was resuspended in 50 mM NaOH. The 
original cell pellet was resuspended in 100 µL TES-Lys buffer (25% sucrose, 1 mM EDTA, 
50 mM Tris-HCl, pH 8.0, 10 mg/mL lysozyme), 1 mM PMSF and 10 mM DTT. Afterwards, 
samples were incubated at 37°C for 30 min and 50 µL 20% SDS was then added to the ly-
sate.
Protein quantification and Western blot analyses
The Bradford method (Bradford, 1976) was used to determine the concentration of 
total proteins extracted from L. lactis. Sodium dodecyl sulfate-polyacrylamide gel electropho-
resis (SDS-PAGE) was performed as described by Laemmli (1970). Western blotting analyses 
were conducted according to Sambrook et al. (1989), using anti-Hsp65 antibodies (1:2500) 
(Farmacore Biotecnologia Ltda.) and rabbit anti immunoglobulin (IgG), conjugated to alka-
line phosphatase (Sigma). The immunodetection blots were scanned and the intensity of the 
Hsp65 signals was compared to that of the positive control used, which was a known amount 
of a purified Hsp65 produced in E. coli (Farmacore Biotecnologia Ltda.).
Endotoxin analysis
The Limulus amebocyte lysate (LAL) test was conducted to check the endotoxin-free 
condition of the wild and recombinant strains of L. lactis, as recommended by European and 
US Pharmacopeias, using the QCL 1000-LAL test kit (Lonza). Briefly, proteins were extracted 
from L. lactis and endotoxin concentrations in the samples were calculated based on a stan-
dard curve, which ranged from 0.025 to 50 endotoxin units (EU)/mL. The absorbance in each 
well was measured at 405 nm.
RESULTS AND DISCUSSION
Construction of recombinant L. lactis strains to produce either cytoplasmic or 
secreted forms of Hsp65 antigen
We produced, for the first time, both cytoplasmic and secreted forms of M. leprae 
Hsp65 in L. lactis strain NCDO2118 using XIES. The choice of XIES was based on some 
advantageous features compared to other expression systems, such as its ability to be switched 
on or off by simply adding either xylose or glucose, respectively (Miyoshi et al., 2004). It is 
less expensive and more secure for laboratory use compared to the other available methods. 
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As described in Material and Methods, two expression vectors were initially constructed, 
pXylT:CYT:hsp65 (cytoplasmic Hsp65 production) and pXylT:SEC:hsp65 (secreted Hsp65 
production). These plasmids are derived from two broad-host-range expression vectors, 
pCYT:Nuc and pSEC:Nuc (Bermudez-Humaran et al., 2003). The former contains i) the 
PxylT promoter (Jamet, 2001), ii) the ribosome-binding site of the lactococcal usp45 gene 
(van Asseldonk et al., 1990), and iii) the DNA fragment encoding the mature part of the 
staphylococcal nuclease, NucB (Le Loir et al., 1994). The latter contains all of this DNA 
sequence, plus the signal peptide of the Usp45 coding sequence (spUsp45), necessary for 
the secretion of NucB.
The vector to target the Hsp65 protein to the cytoplasm of L. lactis (pXylT:CYT:hsp65) 
was obtained as follows: A 1626-bp DNA fragment encoding Hsp65 was PCR-amplified 
from the plasmid pcDNA3:hsp65. Primers were designed using the GenBank nucleotide da-
tabase of the M. leprae TN hsp65 gene (GenBank accession No. M1�3�1). Artifi cial restric-
tion sites (NsiI and EcoRI) and extra bases were introduced into the primers to clone the 
hsp65 ORF in-frame into the expression vector pXylT:CYT:nuc (Table 2). The amplicon 
generated was treated with the enzymes NsiI and EcoRI prior to cloning into purified back-
bone isolated from NsiI-EcoRI-cut pCR®Blunt II-TOPO® cloning vector. The construction 
of this intermediate plasmid (pTP:chsp65) was important because treatment with restriction 
enzymes releases inserts with cohesive extremities; this allowed correct cloning into the L. 
lactis plasmid pXylT:CYT:nuc. The vector pTP:chsp65 was transformed in E. coli TOP10 
and then recovered to confirm the presence of hsp65 by PCR analysis. Later, pTP:chsp65 
was digested with NsiI and EcoRI, and the released fragment was cloned into the purified 
backbone isolated from NsiI-EcoRI-cut pXylT:CYT:nuc, replacing the DNA sequence en-
coding NucB. The vector to direct Hsp65 to the extracellular medium, pXylT:SEC:hsp65, 
was obtained using the same procedures. First, the hsp65 ORF was PCR-amplified from 
pcDNA3:hsp65. The oligonucleotides again contained artificial restriction sites for NsiI and 
EcoRI, along with extra bases, which were added to adapt the reading frame of the spUsp45 
coding sequence (Table 2). The PCR product was digested with NsiI and EcoRI and then 
subcloned into the pCR®Blunt II-TOPO® vector, previously cut with the same restriction 
enzymes. Subsequently, the intermediate plasmid, pTP:shsp65, was introduced into E. coli 
TOP10 by electroporation and then recovered to check for the hsp65 ORF by PCR analysis. 
Subsequently, pTP:shsp65 was cut with NsiI and EcoRI, and the shsp65 fragment, contain-
ing cohesive extremities, was cloned into purified backbone isolated from NsiI-EcoRI-cut 
pSEC:Nuc. The final plasmids, pXylT:CYT:hsp65 or pXylT:SEC:hsp65 (Figure 1), were suc-
cessfully transformed in both E. coli TOP10 and L. lactis NCDO2118. All constructs were 
confirmed by PCR and DNA sequencing analysis.
Primer Sequence
SCFhsp65 (coding strand for the SEC form) 5'-CCATGCATCAGCCAAGACAATTGCGTACG-3'
CTFhsp65 (coding strand for the CYT form) 5'-CCATGCATGCCAAGACAATTGCGTACG-3'
SCTRhsp65 (complementary strand for the CYT and SEC form) 5'-CCGAATTCTCAGAAGTCCATACCACCC-3'
The NsiI site is underlined and the EcoRI site is underlined and in bold. A (in the first line) was added to adapt the 
reading frame of spUsp45.
Table 2. Primers used for the polymerase chain reactions.
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L. lactis is able to produce and secrete LPS-free M. leprae Hsp65
Western blot experiments of xylose-induced and noninduced cultures were conduct-
ed to detect the production of Hsp65 in L. lactis carrying the plasmid pXylT:CYT:hsp65 or 
pXylT:SEC:hsp65, allowing us to characterize the strains. Analysis of induced stationary-
phase cell lysates and culture supernatants demonstrated that both L. lactis (pXylT:CYT:hsp65) 
(hereafter called CYT:hsp65) and L. lactis (pXylT:SEC:hsp65) (hereafter called SEC:hsp65) 
were able to produce and properly direct the recombinant protein. No signal of the antigen was 
detected in the noninduced cultures (Figures 2 and 3). Analysis of protein content showed that 
the band migrated at the expected position (65 kDa), which is the size of M. leprae Hsp65. The 
immunoblotting assay also revealed that this protein was expressed without signs of degrada-
tion, since only one band was detected (Figure 2). Usually, a large number of heterologous 
proteins produced in wild-type L. lactis are degraded by the major extracellular protease, HtrA 
(Poquet et al., 2000). Absence of degradation by this protease can be explained by the fact 
that HSPs are among the most highly conserved proteins, which is evident from its conserved 
DNA and protein sequences (Silva, 1999). This lack of degradation products suggests that L. 
lactis does not recognize this antigen as an exogenous protein. Recombinant Hsp65 (rHsp65) 
produced by induced L. lactis strain CYT:hsp65 was retained in the cytoplasm, as expected, 
since this strain harbors a vector that lacks the spUsp45 coding sequence (lanes CYT:hsp65, 
Figure 2). We also found that induced L. lactis strain SEC:hsp65 secreted large amounts of this 
antigen. We found that approximately 7 mg/L rHsp65 were exported to the extracellular me-
dium. Moreover, the secretion efficiency (ratio of mature protein secreted in the supernatant 
as a fraction of intracellular content of this protein) was estimated to be 50% (Figure 3). Accu-
mulation of rHsp65 within the cytoplasm can be attributed to intrinsic allosteric properties of 
HSPs (Sigler et al., 1998). This protein can bind to polypeptides and alter their conformations; 
consequently, it remains in the cytoplasm and cannot be exported by the L. lactis secretion 
machinery. Few studies have reported the production of recombinant proteins in different cel-
lular locations (i.e., cytoplasm, cell wall or extracellular medium) under the same induction 
conditions and using the same promoter (Le Loir et al., 2005). We demonstrated that rHsp65 
is efficiently produced in both the cytoplasm and secreted forms to the extracellular medium, 
confirming the ability of XIES to produce and correctly target recombinant proteins.
To determine if this antigen was produced without any traces of LPS, the quantity of 
endotoxin in bacterially expressed Hsp65 preparations was evaluated using the chromogenic 
LAL test (Table 3). The samples contained less LPS than the limit set by the FDA, as expected, 
since L. lactis is a Gram-positive bacterium and since this endotoxin occurs as part of the cell 
structure of Gram-negative bacteria (Cardoso et al., 2007). The FDA currently requires the 
LAL test to be performed on all bacterial, human and animal products intended to be used for 
medical proposes. The LPS levels that we found varied from 0.00137-0.01119 ng/µg protein, 
approximately 10-100 times lower than the levels established by the FDA, which stipulates 
that commercial preparations of recombinant proteins must contain less than 1 EU or 0.1 ng 
LPS/µg protein. According to Salek-Ardakani et al. (2002), it is crucial to eliminate or at least 
significantly reduce LPS levels because sub-nanogram quantities can alter the phenotype of 
various cell types, induce complement activation, and cause production of proinflammatory 
cytokines and reactive oxygen species, both in vitro and in vivo. These effects can complicate 
studies of the biological effect of proteins, constituting a serious problem for research on such 
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proteins. For instance, there have been concerns that the reported cytokine-inducing effects 
of HSPs may be a result of something other than the HSPs; they could be due to substances 
bound to HSPs or present as contaminants, such as LPS and lipoproteins (Majde, 1993). Using 
highly purified HSP preparations, a series of papers have demonstrated that the HSP cytokine 
functions are in fact a result of contaminating bacterial products (for example lipoproteins, 
flagellins and mainly LPS) (Tsan and Gao, 2009). Moreover, although several purification pro-
tocols have been developed and can reduce the endotoxin content below the threshold level, 
an absolute guarantee cannot be given. A part of the final product may become accidentally 
contaminated and fail quality control assays, increasing the cost of the final product. Despite 
the development of novel methods designed to remove endotoxins from biological samples, 
more research is needed in this field (Magalhaes et al., 2007). For these reasons, L. lactis is 
an attractive alternative compared to other expression systems, especially E. coli, since it is 
capable of naturally producing LPS-free recombinant proteins.
Figure 2. Cytoplasmic rHsp65 production. Protein extracts of noninduced (Glu lanes) and xylose-induced (Xyl 
lanes) culture samples of Lactococcus lactis NCDO2118 (CYT:hsp65) strain in stationary-phase (OD600 = 2.0) 
were prepared from cell (C lanes) and supernatant (S lanes) fractions and were analyzed by Western blotting using 
anti-Hsp65 antibodies.
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Figure 3. Extracellular rHsp65 production. Protein extracts of noninduced (Glu lanes) and xylose-induced (Xyl 
lanes) culture samples of Lactococcus lactis NCDO2118 (SEC:hsp65) strain in stationary-phase (OD600 = 2.0) 
were prepared from cell (C lanes) and supernatant (S lanes) fractions and were analyzed by Western blotting using 
anti-Hsp65 antibodies.
Lactococcus lactis strain Accepted value in EU/µg Mean EU/µg obtained Final
CYT:hsp65 C I <0.1 0.00881 A
CYT:hsp65 C NI <0.1 0.00501 A
CYT:hsp65 S I <0.1 0.00458 A
CYT:hsp65 S NI <0.1 0.00641 A
SEC:hsp65 C I <0.1 0.00192 A
SEC:hsp65 C NI <0.1 0.00542 A
SEC:hsp65 S I <0.1 0.00137 A
SEC:hsp65 S NI <0.1 0.00205 A
Wild-type strain NCDO2118 C <0.1 0.01119 A
Wild-type strain NCDO2118 S <0.1 0.00225 A
A = approved; C = cellular fraction; S = secreted fraction; I = xylose-induced L. lactis culture; NI = noninduced 
L. lactis culture; EU/µg (endotoxin units/µg) = 0.1 ng LPS/µg protein; CYT:hsp65 = L. lactis producing the 
cytoplasmic form of Hsp65; SEC:hsp65 = L. lactis producing the secreted form of Hsp65.
Table 3. Primers used for the polymerase chain reactions.
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CONCLUSIONS
In conclusion, we engineered recombinant L. lactis strains able to produce and target 
the M. leprae Hsp65 to the cytoplasm or to the extracellular medium. Degradation products, 
related to lactococcal HtrA activity, and LPS contamination were not observed in any fraction 
from induced L. lactis culture samples (CYT:hsp65 and SEC:hsp65). Thus, these strains seem 
to be able to produce and deliver (cytoplasm or extracellular medium) a stable and LPS-free 
form of Hsp65. This alternative expression strategy can open up a wide range of pharmaceuti-
cal and medical applications for this antigen.
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